US2020246508A1PendingUtilityA1

Natural tissue scaffolds as tissue fillers

72
Assignee: LIFECELL CORPPriority: Jul 28, 2011Filed: Feb 24, 2020Published: Aug 6, 2020
Est. expiryJul 28, 2031(~5 yrs left)· nominal 20-yr term from priority
A61L 27/362A61L 27/3633A61L 27/505A61L 2430/00A61L 2300/206A61L 2300/41C08L 5/08A61L 2300/236A61L 2300/252A61L 2300/104A61L 27/54A61L 27/227A61K 38/18A61K 31/728A61L 27/20A61P 31/04A61K 38/1709A61L 27/3604A61L 27/3683A61P 29/00A61L 27/34
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

Claims

exact text as granted — not AI-modified
1 . A tissue filler, comprising:
 an acellular tissue matrix having the ability to maintain the same shape, size, and sponge property after being implanted for one week as was observed prior to application to a tissue site; and   exogenous hyaluronic acid (HA) on a surface of the acellular tissue matrix at a concentration that reduces an inflammatory response or fibrosis when the tissue filler is applied to the tissue site as compared to the same tissue filler not comprising hyaluronic acid.   
     
     
         2 . The tissue filler of  claim 1 , wherein a concentration of HA on the acellular tissue matrix is between approximately 0.5 mg and approximately 5.0 mg per gram of tissue filler. 
     
     
         3 . The tissue filler of  claim 1 , further comprising at least one growth factor. 
     
     
         4 . The tissue filler of  claim 3 , wherein the at least one growth factor is selected from at least one of FGF, VEGF, PDGF, Angiopoitin-2, or Follistatin. 
     
     
         5 . The tissue filler of  claim 1 , wherein the tissue filler has been treated to reduce a bioburden. 
     
     
         6 . The tissue filler of  claim 1 , further comprising an antimicrobial agent. 
     
     
         7 . The tissue filler of  claim 6 , wherein the antimicrobial agent includes at least one of chlorhexidine (CHX) and silver. 
     
     
         8 . The tissue filler of  claim 7 , wherein the CHX has a concentration between approximately 0.1 mg and approximately 3.0 mg per gram of tissue filler. 
     
     
         9 . The tissue filler of  claim 7 , wherein the silver has a concentration between approximately 0.1 mg and approximately 1.0 mg per gram of tissue filler. 
     
     
         10 . The tissue filler of  claim 1 , wherein the tissue filler is capable of being compressed up to approximately ⅔ of its length or width. 
     
     
         11 . The tissue filler of  claim 10 , wherein the tissue filler is capable of returning to its original dimensions after release of compression. 
     
     
         12 . The tissue filler of  claim 1 , wherein the acellular tissue matrix has a stable three-dimensional structure. 
     
     
         13 . The tissue filler of  claim 1 , wherein the acellular tissue matrix comprises a dermal matrix. 
     
     
         14 . The tissue filler of  claim 13 , wherein the acellular tissue matrix is derived from skin. 
     
     
         15 . The tissue filler of  claim 13 , wherein the acellular tissue matrix is derived from dermis. 
     
     
         16 . The tissue filler of  claim 1 , wherein the acellular tissue matrix is derived from at least one of lung, liver, bladder, muscle, and fat tissue. 
     
     
         17 . The tissue filler of  claim 1 , wherein the acellular tissue matrix is derived from porcine tissue. 
     
     
         18 . The tissue filler of  claim 1 , wherein the acellular tissue matrix comprises an adipose matrix.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.